Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Luna Innovations Reports Fourth Quarter 2008 and Full Year Financial Results

Abstract:
Luna Innovations Incorporated (NASDAQ: LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the fourth quarter and year ended December 31, 2008.

Luna Innovations Reports Fourth Quarter 2008 and Full Year Financial Results

Roanoke, VA | Posted on March 3rd, 2009

As compared to the same quarter last year, fourth quarter 2008 revenues decreased by 26%, from $9.9 million to $7.4 million, gross profit decreased from $3.7 million to $2.3 million, and loss per share increased from $0.11 to $0.19. For the year, revenues increased by 10% from $33.7 million to $36.9 million compared to 2007. Gross profit increased from $12.3 million to $14.0 million, or 14%. The loss per share decreased from $0.77 in 2007 to $0.57 in 2008.

Kent Murphy, Chairman and Chief Executive Officer, provided this overview of Luna's results:

"Through the first three quarters of 2008, revenues increased 24% over the first three quarters of 2007. We were having a strong year until the fourth quarter, when the economy changed dramatically. The lower than expected fourth quarter 2008 revenues were primarily caused by a decline in orders for telecommunications products we believe related to customers reducing their capital expenditures in this uncertain economy. In recognition of this decline, we took the appropriate steps to control our expenses and cash flow. We ended 2008 with $15.5 million in cash, a net increase of approximately $0.3 million for the fourth quarter.

"A major portion of our business is geared toward partnerships with industry leaders in selected market spaces. During 2008, we entered into or continued partnership relationships with global market leaders in surgical robotics, heart bypass equipment, oilfield services, telecommunications equipment, power generation equipment and defense systems. The company continues to make progress towards new opportunities for partnering in solar and wind energy generation, non-robotic medical devices, pharmaceuticals and defense solutions.

"In addition, our Technology Development Division, which provides applied contract research to customers, achieved our planned revenue growth of 15% in 2008 and has continued to be successful in attracting new contract awards in early 2009. We believe our backlog of $29 million as of year-end in new research opportunities will continue to support product development in sensors, nanomedicines and defense in accordance with our long-term business strategy.

"In the fourth quarter, we were awarded work with GE Aviation on a U.S. Army program to develop an integrated corrosion health monitoring system. GE Aviation selected Luna for this project due to our experience and knowledge of aircraft corrosion and materials and our concurrent development efforts in corrosion monitoring, modeling, and prediction. The goals of this Army program are to improve rotorcraft safety, decrease maintenance costs, and increase rotorcraft readiness.

"We also continue to garner interest in our unique organic solar cells, which use patented carbon nanomaterials to capture energy more efficiently than many existing organic solar cells to convert to electricity. Our research was recently published in Nature Materials, and demonstrates an entirely new approach of enhancing organic photovoltaic device performance. We are collaborating with solar cell manufacturers for testing and evaluation of Luna's proprietary nanomaterial technology."

On the outlook for 2009, Murphy commented, "Given these times of economic uncertainty, it is difficult to project 2009 revenue. We currently expect flat to modest revenue growth in 2009. We believe that our development relationships with industry leaders in broadband, alternative energy and healthcare markets, in addition to our opportunities within the federal government, position us to offset some of the uncertainty in our sensing and instrumentation product sales. As the economy recovers, we believe our Luna-branded test & measurement products will be attractive products to address the needs of broadband access and high speed network infrastructure in 2009 and beyond."

Fourth Quarter Financial Highlights

    --  Total revenues for the fourth quarter of 2008 decreased 26% compared to
        the fourth quarter of 2007.
    --  Product and license revenues decreased 63% to approximately $1.4 million
        in the fourth quarter of 2008, compared to $3.7 million in the fourth
        quarter of 2007. Approximately $0.6 million of this decline is
        attributable to a change in the estimated percentage of completion on
        certain product development activities.
    --  Gross profit for the fourth quarter of 2008 decreased to $2.3 million,
        or 31% of total revenues, from $3.7 million, or 37% of total revenues,
        for the corresponding period of 2007. The aforementioned
        percentage-of-completion adjustment alone reduced the fourth quarter
        2008 gross margin by approximately 8 percentage points.
    --  Operating expenses were flat at $4.9 million in the fourth quarters of
        2007 and 2008. Operating expenses for the fourth quarter of 2008 include
        a $0.7 million increase in legal expenses and a reduction of $1.0
        million in incentive compensation costs.
    --  Net loss per share for the fourth quarter of 2008 was $0.19 per share
        from a loss per share of $0.11 for the fourth quarter of 2007.
    --  Cash and cash equivalents totaled $15.5 million at December 31, 2008, as
        compared to $15.2 million at September 30, 2008.

Fourth Quarter Business Highlights

Sensing and Instrumentation

    --  Launched the PHOENIX(TM) 1400 swept tunable benchtop laser, which offers
        best-in-class wavelength precision and tuning linearity.
    --  Demonstrated the feasibility of removing gaseous emboli from the
        bloodstream using our acoustic expertise along with our EDAC(R)medical
        device, which detects and verifies the removal of emboli.

Pharmaceuticals / Nanomedicine

    --  Demonstrated our nanomaterial-based hair growth compounds in topical
        form and successfully repeated efficacy testing by an independent third
        party.
    --  Selected two contrast media agent candidates with the core technology
        for developing targeted agents for imaging both inside blood vessels, or
        intravascular, and in the small structural space between tissues or
        parts of an organ, or interstitial sites.
    --  Demonstrated in vitro that our TRIMETASPHERE(R)-based contrast agent can
        possibly be used to target and image arterial plaque, which could lead
        to improved diagnosis and treatment of coronary artery and other
        diseases.

Technology Development

    --  Demonstrated a new approach of enhancing organic photovoltaic (OPV)
        device performance using Luna's exclusive TRIMETASPHERE(R)carbon
        nanomaterials in place of the empty cage fullerenes. Research published
        in the prestigious journal Nature Materials.
    --  Luna's nanomaterials were independently verified at the U.S. Department
        of Energy's National Renewable Energy Lab (NREL) as setting a new record
        for efficiency of the commercially available P3HT organic solar cell
        polymer.


Year-End Financial Highlights

    --  For the year ended December 31, 2008, total revenues grew $3.2 million,
        or 10%, to $36.9 million, compared to $33.7 million in 2007.
    --  Technology Development Division revenues grew 15% in 2008, increasing
        from $23.4 million for the year ended December 31, 2007 to $26.8 million
        for the year ended December 31, 2008. Product and license revenue was
        $10.1 million in 2008 as compared to $10.3 million in 2007.
    --  Gross profit increased to $14 million, or 38% of revenues, for 2008,
        from $12.3 million, or 37% of revenues, in 2007.
    --  Operating expenses were $21.3 million in 2008, compared to $20.6 million
        in 2007.
    --  Net loss from operations was $7.3 million in 2008, versus a loss from
        operations of $8.3 million for the prior year, an improvement of 12%.
    --  For the first nine months of 2008, prior to the global economic crisis,
        the company had increased revenues by 24% and improved its net loss by
        33% compared to the first nine months of 2007.
    --  The net loss applicable to common stockholders for 2008 was $6.3
        million, or $0.57 per share on a diluted basis, compared to the net loss
        applicable to common stockholders of $7.8 million, or $0.77 per share on
        a diluted basis, for 2007.
    --  Entered into a $10 million credit facility with Silicon Valley Bank,
        including a four-year term debt of $5 million outstanding as of December
        31, 2008, with the remaining facility available under a revolving line
        of credit.

Year-End Business Highlights

Sensing and Instrumentation

    --  Luna Technologies' common optical platform continues into expanding
        markets, including medical devices, both robotic and non-robotic
        monitoring, energy generation and delivery monitoring. We are currently
        meeting the development objectives and timeline of our partnership with
        Intuitive Surgical to adapt Luna's shape sensing technology for use in
        medical robotics for minimally invasive surgery. We are applying our
        shape sensing technology to underwater surveillance arrays, which may
        allow the Navy to detect and assess enemy threats in the ocean with
        greater accuracy. We are also applying our shape technology in a joint
        program with a leading global security company developing a flexible
        positioning system for manufacturing metrology.
    --  Launched Luna's first tunable laser (our PHOENIX(TM)1000 device), which
        provides users with a high-performance, rugged and cost-effective
        tunable laser solution for applications in fiber sensing, metrology,
        spectroscopy and instrumentation. Launched the Precision Reflectometer
        (PR(TM) 4400) instrument for increased throughput in optical
        manufacturing.

Pharmaceuticals / Nanomedicine

    --  Selected to work with the National Cancer Institutes' National
        Characterization Labs (NCL) in preclinical studies, with the intent of
        accelerating the transition of basic nanomedicine research into clinical
        applications.
    --  Results from animal studies reinforced findings that Luna's nanomedicine
        prototype encourages existing hair follicles to grow, hair to grow
        faster and the numbers of hair follicles to increase.
    --  During 2008, received several new projects from the National Institutes
        of Health (NIH) covering areas of allergic response, MRI contrast, and
        nanomedicines.

Technology Development

    --  Development milestone met with the Missile Defense Agency on the contact
        for development of low cost common, sensor electronics for use in
        next-generation exoatmospheric interceptor kill vehicles for ballistic
        missile defense. A successful technology-demonstration flight test was
        made from the NASA Wallops Flights Facility, Virginia on June 26, 2008.
    --  Awarded $3.9 million subcontract from General Dynamics Information
        Technology in support of an Air Force Research Laboratory (AFRL) prime
        contract to continue work improving the performance of nanomaterials for
        military applications

Outlook 2009

The company expects flat to modest growth in 2009 with total revenue to be in the range of approximately $37 million to $40 million, consisting of product and license revenue of approximately $7 to $9 million and technology development revenue of approximately $30 to $31 million. Also for 2009, the company anticipates a net loss in the range of approximately $5.5 to $6.0 million.

For the first quarter of 2009, the company expects revenue of approximately $9 million and a net loss of approximately $2.2 million.

Conference Call Information

As previously announced, Luna Innovations will conduct an investor conference call at 11:00 a.m. (EST) today to discuss its financial results and business developments for 2008 and expectations for 2009. The call can be accessed by dialing 1.866.770.7129 domestically or 1.617.213.8067 internationally prior to the start of the call. The access code is 54417420. The conference call will also be webcast live over the Internet. The webcast can be accessed by logging on to the "Investor Relations" section of the Luna Innovations website, prior to the event. The webcast will be archived under the "Webcasts and Presentations" section of the Luna Innovations website for at least 30 days following the conference call.

####

About Luna Innovations Incorporated

Luna Innovations Incorporated is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.

Forward Looking Statements:

This release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding, but not limited to, (i) expectations regarding Luna's customers and the effects of the current economic crisis; (ii) Luna's actions to react to a downturn in customer purchases; (iii) expectations for partnerships with industry leaders; (iv) expectations regarding Luna's technology and product development contracts including those with GE Aviation, the National Renewable Energy Lab, Intuitive Surgical, the National Cancer Institutes' National Characterization Lab, the Missile Defense Agency and General Dynamics; (v) expectations regarding the successful development and commercialization of certain technologies including sensors, organic solar cells, nanomaterial-based hair growth compounds and contrast agents, and sensor electronics; (vi) expectations regarding Luna's contract backlog and continued growth thereof; (vii) expectations of capabilities and success of new products including the PHOENIXTM 1400 laser; (viii) anticipated revenues and activity in its product and license and technology development divisions in 2009 and the corresponding financial results for each of those areas; and (ix) Luna's financial outlook for its first quarter and full fiscal year 2009, including expected revenues and net loss as well as the underlying growth rates assumptions and expected components thereof. The company attempts, whenever possible, to identify forward-looking statements by words such as "intends," "will," "plans," "anticipates," "expects," "may," "estimates," "believes," "should," "projects," or "continue," or the negative of those words and other comparable words. Similarly, statements that describe the company's business strategy, goals, prospects, opportunities, outlook, objectives, plans or intentions are also forward-looking statements. Actual events or results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond the company's control. Factors that could cause actual results to differ materially from the expectations expressed in such forward-looking statements include, but are not limited to, continued or further weakness in the global economy; the company's ability to transition its revenue mix to product revenues; risks inherent in current or future litigation proceedings; the company's ability to successfully identify market needs for new products; the company's continued reliance on contract research, including government grants and contracts available only to small businesses, for a significant portion of its revenue; the company's ability to remain eligible for small business government grants and contracts in the future; technical difficulties in developing or engineering new products or in meeting contract research requirements; the company's ability to manage its cash and costs as well as to raise additional capital; competition from alternative, more affordable energy sources; the potential adverse effects of nanotechnology, whether real or perceived; and the potential limitations of regulatory requirements in obtaining clearance by the U.S. Food and Drug Administration or other regulatory agencies for the company's products. Additional factors that may affect the future results of the company are set forth in the company's quarterly and annual reports on Form 10-Q and Form 10-K, respectively, and other filings with the Securities and Exchange Commission ("SEC"), which are available at the SEC's website at http://www.sec.gov, and at the company's website at http://www.lunainnovations.com. These risk factors are updated from time to time through the filing of periodic reports with the SEC. The statements made in this press release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements herein after the date of this press release.


Luna Innovations Incorporated Consolidated Statements of Operations

                  Three Months Ended              Twelve Months Ended

                  December 31,                    December 31,

                    2008            2007            2008            2007

                  (unaudited)                     (unaudited)

Revenues:

 Contract
 research         $ 6,042,895     $ 6,265,004     $ 26,838,592    $ 23,356,456
 revenues

 Product and
 license            1,353,654       3,671,462       10,059,728      10,325,659
 revenues

  Total             7,396,549       9,936,466       36,898,320      33,682,115
  revenues

Cost of
revenues:

 Contract           4,067,511       4,626,536       17,626,495      16,546,140
 research costs

 Product and        1,008,369       1,648,822       5,231,067       4,819,825
 license costs

  Total cost of     5,075,880       6,275,358       22,857,562      21,365,965
  revenues

Gross               2,320,669       3,661,108       14,040,758      12,316,150
Profit

Operating           4,864,826       4,870,622       21,334,655      20,570,479
expense

Operating           (2,544,157 )    (1,209,514 )    (7,293,897 )    (8,254,329 )
loss

Other income        -
(expense)

 Other income       530,628         (18,112    )    1,197,755       32,722
 (expense)

 Interest income
 / (expense),       (147,684   )    76,231          (189,501   )    371,991
 net

Total other         382,944         58,119          1,008,254       404,713
income (expense)

Loss before         (2,161,213 )    (1,151,395 )    (6,285,643 )    (7,849,616 )
income taxes

Income tax
expense             -
(benefit)

Net               $ (2,161,213 )  $ (1,151,395 )  $ (6,285,643 )  $ (7,849,616 )
loss

Net loss per
share:

 Basic            $ (0.19      )  $ (0.11      )  $ (0.57      )  $ (0.77      )

 Diluted          $ (0.19      )  $ (0.11      )  $ (0.57      )  $ (0.77      )

Weighted average shares:

 Basic              11,118,249      10,465,501      10,974,010      10,219,711

 Diluted            11,118,249      10,465,501      10,974,010      10,219,711




Luna Innovations Incorporated Consolidated Balance Sheets

                                              December 31,     December 31,

                                                2008             2007

Assets                                        (unaudited)

Current assets

 Cash and cash equivalents                    $ 15,518,960     $ 12,046,945

 Accounts receivable, net                       7,332,034        9,716,610

 Refundable income taxes                        98,092           396,062

 Inventory                                      2,828,991        1,675,239

 Other current assets                           342,598          333,105

       Total current                            26,120,675       24,167,961
       assets

Property and equipment,                         5,363,957        5,859,515
net

Intangible assets,                              1,813,643        1,911,132
net

Deferred tax asset                              600,000          600,000

Other assets                                    118,292          10,270

             Total assets                     $ 34,016,567     $ 32,548,878

Liabilities and stockholders'
equity

Current liabilities

 Current portion of capital lease             $ 17,396         $ 23,885
 obligation

 Current portion of long-term debt              1,428,572        -
 obligation

 Accounts payable                               2,667,192        3,024,973

 Accrued liabilities                            5,161,308        5,331,798

 Deferred credits                               1,854,282        1,672,400

       Total current                            11,128,750       10,053,056
       liabilities

Long-term capital lease                         -                4,671
obligation

Long-term debt obligation                       8,571,428        5,000,000

Deferred credits and other long term            -                354,418
liabilities

       Total liabilities                        19,700,178       15,412,145

Stockholders'
equity:

       Preferred stock, par value $0.001,
       5,000,000 shares authorized at           -                -
       December 31, 2008, no shares issued
       and outstanding at December 31, 2007

 Common stock

       Common stock, par value $0.001,
       100,000,000 shares authorized            11,138           10,704
       11,137,882 shares issued and
       outstanding at December 31, 2008

 Additional paid-in                             37,960,928       34,496,063
 capital

 Accumulated deficit                            (23,655,677 )    (17,370,034 )

       Total stockholders'                      14,316,389       17,136,733
       equity

             Total liabilities and            $ 34,016,567     $ 32,548,878
             stockholders' equity





Luna Innovations Incorporated Consolidated Statements of Cash
Flows

                                               Twelve Months Ended

                                               December 31,

                                                 2008               2007

                                               (unaudited)

Cash flows used in operating
activities

 Net loss                                      $ (6,285,643    )  $ (7,849,616 )

 Adjustments to reconcile net loss
 to net

  cash provided by operating
  activities:

  Depreciation and amortization                  1,933,566          1,780,877

  Deferred income taxes                        -                    -

  Share-based compensation                       2,867,487          2,425,143

 Change in assets and liabilities:

  Accounts receivable                            2,384,576          (2,483,204 )

  Refundable income taxes                        297,970            -

  Other assets                                   (1,626,131    )    (659,205   )

  Accounts payable and accrued                   (157,628      )    1,972,111
  expenses

  Deferred revenues                              (172,536      )    597,724

   Net cash used in operating                    (758,339      )    (4,216,170 )
   activities

Cash flows used in investing
activities

 Acquisition of property and                     (391,210      )    (1,375,612 )
 equipment

 Intangible property costs                       (536,251      )    (414,328   )

   Net cash used in investing                    (927,461      )    (1,789,940 )
   activities

Cash flows from financing activities

 Borrowings on term loan                         5,000,000

 Payments on debt obligation                     -                  (214,953   )

 Payments on capital lease                       (11,160       )    (84,695    )
 obligations

 Proceeds from the exercise of options and       168,975            485,950
 warrants

   Net cash from financing                       5,157,815          186,302
   activities

Net change in cash                               3,472,015          (5,819,808 )

Cash - beginning of period                       12,046,945         17,866,753

Cash - end of period                           $ 15,518,960       $ 12,046,945



For more information, please click here

Contacts:
Luna Innovations Incorporated
Investor Contact:
BPC Financial Marketing
John Baldissera
1-800-368-1217

or
Media Contact:
Luna Innovations Incorporated
Karin Clark
1-540-769-8400

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

'Life Redesigned: The Emergence of Synthetic Biology' Lecture at Brookhaven Lab on Wednesday, April 30: Biomedical Engineer James Collins to Speak for BSA Distinguished Lecture Series April 16th, 2014

ECHA Planning Workshop on Regulatory Challenges in the Risk Assessment of Nanomaterials April 16th, 2014

Nanomedicine

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

PAM-XIAMEN Offers UV LED wafer April 15th, 2014

Announcements

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Financial Reports

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014

Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014

Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE